VistaGen Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for anxiety, depression and certain additional central nervous system disorders. Co.'s product candidates include: PH94B, which is a neuroactive nasal spray with therapeutic potential in a range of indications involving anxiety or phobia; PH10, which is a synthetic neurosteroid delivered intranasally that has therapeutic potential in a range of neuropsychiatric indications involving depression; and AV-101 (4-Cl-KYN), which is an oral prodrug that targets the N-methyl-D-aspartate receptor, an ionotropic glutamate receptor in the brain.